Aim: The prevalence of thyroid nodules and the risk of thyroid cancer in patients with Graves' disease is uncertain. We aimed to evaluate the prevalence of thyroid nodules and cancer in patients with Graves' disease.
Methods: Retrospective observational study of adult subjects with Graves' disease (positive autoantibodies thyrotropin receptor antibodies (TRAbs)) between 2017 and 2021 at our center was done. We evaluated the prevalence of thyroid nodules and cancer in this population and characterized the predictive factors for thyroid malignancy using linear and logistic regression models.
Results: We evaluated a total of 539 patients with Graves' disease during a median follow-up of 3.3 years (25th-75th percentiles 1.5-5.2 years). Fifty-three percent had thyroid nodules and 18 (3.3%) were diagnosed with thyroid cancer (12 papillary microcarcinomas). All tumors were classified using TNM classification as T1, and only one had lymph node metastasis; there were no recordings of distant metastasis. Sex, age, body mass index, smoking, TSH, and TRAbs levels were not significantly different between patients with and without thyroid cancer. Patients with multiple nodules on ultrasound (OR 1.61, 95%CI 1.04-2.49) and with larger nodules (OR 2.96, 95%CI 1.08-8.14, for 10 mm increase in size) had a greater risk of thyroid cancer diagnosis.
Conclusion: Patients with Graves' disease had a high prevalence of thyroid nodules and their nodules had a significant risk of thyroid cancer. The risk was higher in those with multiple and larger nodules. Most had low-grade papillary thyroid cancer. More studies are needed to clarify the clinical relevance of these findings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388649 | PMC |
| http://dx.doi.org/10.1530/ETJ-23-0055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Erythrocyte modified controlling nutritional status as a biomarker for predicting poor prognosis in post-surgery breast cancer patients.
Sci Rep
January 2025
School of Medicine, Shaoxing University, Shaoxing, 312000, Zhejiang, China.
Nutrition and inflammation are closely related to prognosis in breast cancer patients. However, current nutritional and inflammatory measures predict disease free survival (DFS) of breast cancer are still different, and the most predictive measures remain unknown. This study aimed to compare the predictive effects of commonly used nutritional and inflammatory measures on DFS and to improve existing nutritional or inflammatory measures in order to develop a new model that is more effective for predicting postoperative recurrence and metastasis in breast cancer patients.
View Article and Find Full Text PDFApplication of Raman Spectroscopy in the Non-invasive Diagnosis of Urological Diseases via Urine.
Photodiagnosis Photodyn Ther
January 2025
Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China; Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China. Electronic address:
Objectives: The objective of this review is to provide a comprehensive overview of the utilization of Raman spectroscopy in urinary system diseases, highlighting its potential in non-invasive diagnostic methodologies for early diagnosis and prognostic assessment of urinary ailments.
Methods: We searched PubMed, Web of Science, and Google Scholar using 'raman,' 'bladder,' 'kidney,' 'prostate,' 'cancer,' 'infection,' 'stone or urinary calculi,' and 'urine or urinary,' along with 'AND' and 'OR' to refine our search. We excluded irrelevant articles and screened potential ones based on titles and abstracts before assessing the full texts for relevance and quality.
Risk of Osteoporotic Fractures among Patients with Thyroid Cancer: A Nationwide Population-Based Cohort Study.
Endocrinol Metab (Seoul)
January 2025
Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Background: The associations between thyroid cancer and skeletal outcomes have not been thoroughly investigated. We aimed to investigate the risk of osteoporotic fractures in patients with thyroid cancer compared to that in a matched control group.
Methods: This retrospective cohort study included 2,514 patients with thyroid cancer and 75,420 matched controls from the Korean National Health Insurance Service-National Sample Cohort (NHIS-NSC, 2006-2019).
Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis.
Endocrinol Metab (Seoul)
January 2025
Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, India.
Background: Data on the carcinogenic potential of tirzepatide from randomized controlled trials (RCTs) are limited. Furthermore, no meta-analysis has included all relevant RCTs to assess the cancer risk associated with tirzepatide.
Methods: RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases.
Can we diagnose noninvasive follicular thyroid neoplasm with papillary-like nuclear features before surgery?
Updates Surg
January 2025
Department of Surgery, MacKay Memorial Hospital, 92, Chung-Shan North Road, Section 2, Taipei, 104217, Taiwan.
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) can be differentiated from invasive encapsulated follicular variant of papillary thyroid carcinoma (eFV-PTC) by the presence of a tumor capsule or blood vessel invasion in histological examination. The objective of this study was to investigate whether it is possible to distinguish between NIFTP and invasive eFV-PTC before surgery. Patients diagnosed with NIFTP and invasive eFV-PTC from 2017 to 2023 were analyzed for biochemical, ultrasonographic, and cytological features.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!